Smart Biopsy System
Dune Medical Devices was selected as one of the few recipients of the European Union Horizon 2020 research grant to spur development of our biopsy system. This new product will expand our surgical oncology portfolio to include a soft tissue biopsy system with its first indication in breast tissue.
This project has received funding from the European Union’s Horizon 2020 research and innovation program.
We are implementing a go-to-market strategy expanding into new countries. To lead this initiative an 18-month study is being conducted across the U.K. and will look at the health, cosmetic and financial impact of MarginProbe for lumpectomy patients.
Exploring New Indications
Margins matter in many cancer indications. MarginProbe was initially FDA approved for breast cancer patients and we are now looking to expand our ground breaking technology into additional indications such as prostate, colon, lung and pancreas.
View the study by clicking here.
We want to hear from you! If you would like to know more about Dune products coming to your country or would like to help us pave the way for our technology in other cancer indications please contact us.
Do you want to be up to date?